Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Immunotherapy targeting the PD-1/PD-L1 pathway had previously been shown to be efficacious in
the treatment of patients with metastatic head and neck squamous cell carcinomas.
Stereotactic Body Radiotherapy (SBRT) to metastatic lesions causes localized cancer cell
killing and the release of cancer cell debris, which could stimulate the immune system in the
presence of immunotherapy. The purpose of this study is to assess the tolerability and
efficacy of combining Durvalumab (MEDI4736), Tremelimumab and SBRT in controlling cancer
progression. SBRT will be administered to patients while they are receiving Durvalumab and
Tremelimumab.